摘要
目的探讨磷酸肌酸钠联合心肌康颗粒治疗小儿病毒性心肌炎的临床效果,为临床治疗提供参考。方法选择2011年1月至2015年1月160例病毒性心肌炎患儿,按照数字表法随机分为对照组与观察组,各80例。对照组使用果糖二磷酸钠、维生素C、辅酶Q10、利巴韦林等对症治疗,观察组在对照组基础上,联合使用磷酸肌酸钠及心肌康颗粒治疗,比较两组患者临床效果、心电图改善、心肌酶水平及肌钙蛋白I(cTnI)水平变化。结果观察组治疗有效率为87.50%,明显高于对照组的70.00%,差异有统计学意义(χ2=7.320,P=0.004);观察组心电图改善有效率为90.00%,明显高于对照组的75.00%,差异有统计学意义(χ2=6.234,P=0.005);两组患者治疗后比治疗前天门冬氨酸氨基转移酶(AST)、磷酸肌酸酶(CPK)、乳酸脱氢酶(LDH)、肌酸激酶同工酶(CK-MB)、羟丁酸脱氢酶(HBDH)、cTnI均有明显改善,差异有统计意义(P<0.05),观察组治疗后AST、CPK、LDH、CK-MB、HBDH、cTnI分别为(29.98±4.66)U/L、(184.41±5.97)U/L、(314.25±9.84)U/L、(22.29±2.98)U/L、(268.37±8.64)U/L、(0.13±0.04)μg/L,与对照组[(33.49±4.98)U/L、(196.49±6.71)U/L、(328.64±11.14)U/L、(26.53±3.44)U/L、(298.68±10.64)U/L、(0.25±0.05)μg/L]比较差异有统计学意义(P<0.05)。结论磷酸肌酸钠联合心肌康颗粒治疗小儿病毒性心肌炎临床效果显著,值得临床推广应用。
Objective To investigate the clinical effect of creatinine phosphate sodium combined with Xinjikang Granules in treating children with viral myocarditis,and provide reference for clinical treatment.Methods 160 children patients with viral myocarditis from January 2011 to January 2015 were selected and randomly divided into the control group and the observation group according to the digital table method,80 cases in each group.The control group used the symptomatic treatment of fructose diphosphate（FDP）,vitamin C,coenzyme Q10 and ribavirin,while the observation group used creatine phosphate sodium and Xinjikang Granules on the basis of control group.The clinical effects,ECG improvement,cardiac enzymes and troponin I levels were compared between the two groups.Results The effective rate in the observation group was 87.50%,which was significantly higher than70.00%in the control group,the difference was statistically significant（χ2=7.320,P=0.004）;the effective rate of ECG improvement in the observation group was 90.00%,which was significantly higher than 75.00%in the control group,the difference was statistically significant（χ2=6.234,P=0.005）;the levels of AST,CPK,LDH,CK-MB,HBDH and cTnI after treatment in the two groups were significantly improved compared with before treatment,the differences were statistically significant（P〈0.05）,the levels of AST,CPK,LDH,CK-MB,HBDH,and cTnI after treatment in the observation group were（29.98±4.66）U/L,（184.41±5.97）U/L,（314.25±9.84）U/L,（22.29±2.98）U/L,（268.37±8.64）U/L and（0.13±0.04）μg/L respectively,which showed the statistical differences compared with the control group,[（33.49±4.98）U/L、（196.49±6.71）U/L、（328.64±11.14）U/L、（26.53±3.44）U/L、（298.68±10.64）U/L、（0.25±0.05）μg/L,P〈0.05].Conclusion Creatinine phosphate sodium in treating children with viral myocarditis has significant clinical effect,and is worthy of clinical promotion and application.
出处
《重庆医学》
CAS
北大核心
2016年第10期1343-1344,1347,共3页
Chongqing medicine
关键词
磷酸肌酸
患儿
病毒性心肌炎
phosphocreatine
children patients
viral myocarditis
